AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Shinsan M. Su, Jeremy Travins et al.|Cancer Discovery|2017Cited by 457
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albigès, Fabrice Barlési, Annabelle Stoclin et al.|Nature Cancer|2020Cited by 119
Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic MalignanciesAline Renneville, Benjamin L. Ebert, Jessica A. Gasser et al.|Blood Cancer Discovery|2021Cited by 46